Dimethyl fumarate 240mg gastro-resistant capsules
NHS hospitals in England used £92,112,782 of indicative cost of Dimethyl fumarate 240mg gastro-resistant capsules in the 12 months to July 2026, about 0.4% of all hospital medicines spend. That is down 10.9% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Dimethyl fumarate 240mg gastro-resistant capsules: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to July 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Dimethyl fumarate 240mg gastro-resistant capsules most
By indicative cost over the 12 months to July 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| University College London Foundation Tr | £4,535,642 |
| Sheffield Teaching Hospitals Nhs Trust | £3,916,216 |
| University Hospital Southampton Nhs Ft | £3,624,772 |
| Leeds Teaching Hpls Nhs Trust | £3,514,064 |
| The Walton Centre Nhs Foundation Trust | £3,457,658 |
| Salford Royal Nhs Foundation Trust | £3,423,511 |
| Cambridge Univ Hosp Nhs Foundation Trust | £3,320,372 |
| Nottingham University Hospitals Trust | £3,071,384 |
| University Hpls Of Leicester Nhs Trust | £2,877,860 |
| Western Sussex Hospitals Nhs Found Trust | £2,744,176 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.